Aspire Biopharma (ASBP)
Developer of sublingual drug and supplement formulations, including aspirin candidates and Buzz Bomb.
Something off on this page? Send us feedback.
Develops sublingual formulations of known drugs and supplements, sells Buzz Bomb caffeine products, and advances a high-dose aspirin candidate. Current revenue is from nutraceutical sales, while potential pharmaceutical income depends on development, regulatory approval, and a contractor-led supply model.
Develops sublingual powder and granule formulations of known drugs and supplements, intended to support rapid absorption. Its product and development lines include the high-dose aspirin candidate for suspected acute myocardial infarction, Buzz Bomb caffeine supplement, low-dose aspirin, sublingual melatonin, vitamins D, E, and K, and exploratory drug formulations.
Generates current product revenue from nutraceutical sales and expects prospective revenue to include direct product sales, development funding, upfront and milestone payments, royalties, and licensing. Sales are primarily to U.S. customers, with smaller amounts in Canada and other geographies.
Relies on contract manufacturers for clinical and commercial supply, rather than owning manufacturing facilities. The delivery mechanism itself has not received FDA approval, while the lead aspirin program requires additional clinical development and has no established sales, marketing, or distribution infrastructure.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $12.2M · Total debt $0 · Total assets $13.5M · Shareholders' equity $11.8M
- Revenue
- $63.1K
- Operating income
- −$2.4M
- Net income
- −$1.3M
No dividends on record.
| Institutions | 0.06% | 845 shares | |
|---|---|---|---|
| 2 holders · as of Mar 31, 2026 | |||
| Insiders | 0.00% | 17 shares | |
| 1 holder · as of Jun 10, 2025 | |||
| Other | 99.94% | 1.40M shares | |
| remainder | |||
1.40M company shares as of Sep 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (1.40M in the company's Sep 22, 2026 report, 115.4K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Crossingbridge Advisors, LLCInstitution | 0.06% | 24,348 | as of Mar 31, 2026 |
Hallmark Capital Management IncInstitution | 0.00% | 1,000 | as of Mar 31, 2026 |
Donald G. FellInsiderdirector | 0.00% | 17 | filed Jun 10, 2025 |
Gary ShirinyanInsider | —7.70% of class, as filed | — | filed Aug 10, 2026 |
Highbridge Capital Management, LLCStrategic | —5.20% of class, as filed | — | filed May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Haleon (ADR)
OTC pain relief and faster-absorption formats via Advil.
- Kenvue
OTC analgesic rival through Tylenol pain-relief products.
- Aquestive Therapeutics
Sublingual drug-delivery platform benchmark using PharmFilm.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aspire Biopharma | $8.20 | −0.17% | $1.0M | — | — | 10.3 | — |
| Haleon (ADR) | $9.29 | +0.49% | $41.22B | 19.5 | — | 2.8 | +3.7% |
| Kenvue | $17.80 | −0.42% | $33.93B | 20.3 | 15.0 | 2.2 | +3.0% |
| Aquestive Therapeutics | $4.91 | −0.61% | $599.7M | — | — | 11.1 | +38.2% |
| Median | 19.9 | 15.0 | 2.8 | +3.7% |